Clinical Trials Logo

Endometrial Adenocarcinoma clinical trials

View clinical trials related to Endometrial Adenocarcinoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03836157 Withdrawn - Endometrial Cancer Clinical Trials

Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer

Start date: May 31, 2019
Phase: Phase 2
Study type: Interventional

IMGN853 is designed to inhibit cell division and cell growth of folate receptor 1 (FRĪ±)-expressing tumor cells. The purpose of this study is to test the safety of IMGN853 and bevacizumab and see what effects (good and bad) that this combination treatment has on subjects with recurrent endometrial cancer.

NCT ID: NCT01943058 Withdrawn - Clinical trials for Endometrial Adenocarcinoma

Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer

Start date: March 2014
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well megestrol acetate or levonorgestrel-releasing intrauterine system works in treating patients with atypical endometrial hyperplasia or endometrial cancer. Progesterone can cause the growth of endometrial cancer cells. Hormone therapy using megestrol acetate or levonorgestrel-releasing intrauterine system may fight endometrial cancer by lowering the amount of progesterone the body makes. It is not yet known whether megestrol acetate is more effective than levonorgestrel-releasing intrauterine system in treating atypical endometrial hyperplasia or endometrial cancer.